| Editor's Note: We had a technical snafu this morning. Our link below for Karim's "Insider Code" was not working. Sorry for our case of the Mondays! Below is a fixed link so you can attend this urgent event, this Thursday at 2 p.m. EST. Click here to unlock FREE access to Karim's Inside Code event! (By submitting your email address, you will receive free updates for the Insider's Code Event , and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.) Rest of today's update is posted below. Happy trading, The Trade of the Day Team
Good morning Wake-Up Watchlisters! While you're sipping coffee you'll see stock futures dipped on Monday. Investors are still weary about inflation numbers after Federal Reserve Governor Christopher Waller said that policymakers have 'a ways to go' before ending interest-rate hikes. While signs of cooling inflation led the S&P 500 to its best week since June last week, it appears we're not out of the woods yet. With the markets still volatile, it's tough to know exactly when they will head back up… consistently. That's why it's important to pay attention to what insiders DO rather than what they SAY. Tracking insider buying is exactly what our Head Fundamental Tactician Karim Rahemtulla does as part of his Insider Matrix. And this week, he's revealing his 'InsiderCode Strategy' that will show you exactly how to apply this powerful trading strategy in real time. You'll be able to see trades as they happen, including Karim's 3 favorite insider plays right now. Click here to get on the list. (By submitting your email address, you will receive free updates for the Insider's Code Event , and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.) Here's a look at the top-moving stocks this morning. Opiant Pharmaceuticals (Nasdaq: OPNT) Opiant Pharmaceuticals is up 119.89% premarket after agreeing to be acquired by Indivior PLC (INDV). Under the agreement, Indivior will acquire all of the outstanding shares of Opiant for upfront consideration of $20 per share. The acquisition will expand indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize the launch of OPNT003, a potential treatment for opioid overdose. Redhill Biopharma (Nasdaq: RDHL) Redhill Biopharma is up 23.27% premarket after the company reached an agreement in principle with HCR Collateral Management to extinguish all debt obligations in exchange for the transfer of RedHill's rights in Movantik™ (naloxegol). It is expected that RedHill would provide transition services to HCR to ensure a seamless process so patient care will not be interrupted. | 
Post a Comment
Post a Comment